$ANTX News

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates

AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target

AN2 Therapeutics Inc (NASDAQ:ANTX) Pipeline Progress Outshines Slight Q1 Earnings Miss

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies

AN2 Therapeutics Files Prospectus To Offer And Sell Up To $300M Of Securities

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies; Co. May Issue And Sell From Time To Time Up To An Aggregate Of $80M Of Shares Of The Company's Common Stock

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate

AN2 Therapeutics Stock Cools Off After 90% Rally

Monday's session: top gainers and losers

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics shares are trading higher after the company announced it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million.

AN2 Therapeutics shares are trading higher after the company announced it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million.

AN2 Therapeutics Announces $40 Million Private Placement Financing